Sea You at Fetch Long Beach
News|Articles|May 16, 2023

VolitionRx publishes new research in PLOS ONE

Author(s)dvm360 Staff

This new study demonstrates nucleosome concentrations are useful when treating canine cancer treatment monitoring

VolitionRx Limited announced that it published a study in PLOS ONE that reveals plasma nucleosome concentrations are a useful tool for treatment monitoring and disease progression for dogs suffering from hematopoietic cancers.

According to an organizational release,1 the study was led by Heather Wilson-Robles, DVM, DACVIM (Oncology), chief medical officer and lead veterinary Volition Veterinary, and conducted at the Small Animal Clinical Sciences Department at Texas A&M University. Wilson-Robles and her team completed the study using Volition’s nucleosome quantification technology.

“Veterinarians typically rely on physical exam findings, radiographs, ultrasound, and baseline blood work to monitor dogs with hematopoietic cancers for treatment response and remission status. However, to date, there has been a lack of useful circulating biomarkers available in veterinary medicine,” explained Wilson-Robles, in the release.1

While using Nu. Q Vet Cancer for the study, the findings showed that plasma nucleosome concentration correlated better with response and progression of disease compared to thymidine kinas or C-reactive protein.1

"We found that plasma nucleosome concentrations were significantly higher at diagnosis and progressive disease than they were when dogs were in remission. The study also showed that nucleosome concentrations nearly always returned to the low range during treatment and are associated with clinical remission. In addition, nucleosome elevations often recur at the time of disease progression, mirroring the clinical course of the disease and that higher nucleosome levels are inversely correlated with survival," she concluded.

Reference

Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring. News release. Volition. May 11, 2023. Accessed May 16, 2023. https://volition.com/resources/press-room/press-releases/volition-study-nucleosome-concentrations-tool-canine-cancer-treatment-monitoring


Related to this article

Laverdia now available for purchase for dogs with lymphoma
Verdinexor tablets are now available for dogs with lymphoma after receiving full FDA approval earlier this year, offering an at-home treatment option given twice weekly and showing a longer time to disease progression than the control in a field study.
Q&A: Caregiver burden can begin early in pet illness. Are veterinary teams equipped to support clients, and how can veterinary social workers help both parties?
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
Inside veterinary social work
In a slideshow drawn from an on-site dvm360 interview at the 2026 Fetch National Harbor Veterinary Conference, a veterinary oncologist and a veterinary social worker walk through how the role supports owners and staff across a pet's cancer diagnosis, treatment, and end-of-life care.
Q24h
We all get the same 24 hours, whether you are a new graduate drowning in student debt, a technician working a double, or Ariana Grande on tour.